Operator
Good afternoon. This is the Chorus Call conference operator. Welcome, and thank you for joining the DiaSorin Full Year 2025 Results Conference Call. [Operator Instructions]
At this time, I would like to turn the conference over to Mr. Carlo Rosa, CEO of DiaSorin. Please go ahead, sir.
Carlo Rosa
CEO, GM & Executive Director
Thank you, operator. Ladies and gentlemen, good afternoon, and welcome to the DiaSorin full year results.
Today, we have a busy agenda. I’m going to make some business remarks. Then our current CFO, Mr. Pedron is going to take us through the 2025 financials, our future CFO, Mr. Alberto is going to discuss about guidance 2026, and then collectively, we’re going to take questions.
So let me start from 2025 business comments. 2025, I think, marked a year of good achievement for our company with success for our strategy in the different technologies with Immuno delivering 7% growth, Molecular Diagnostics year-on-year flat and we’ll see later primarily related to the fact that the flu season this year is — has been very weak. And then LTG delivering to expectation flattish compared to previous year. And again, we will discuss later, primarily due to the fact that on the Life Science segment, as I think is very well known by everybody, 2025 has not been an exciting year.
